Objective. Comparison of overall RA-related costs and of relative contribution of single-cost domains before and after the introduction of TNF-blocking agents in Germany.
Introduction
Various studies have investigated socioeconomic and cost issues in RA from different perspectives [1] . High costs related to medical and non-medical resource consumption and to productivity losses such as sick leave and work disability have been reported showing the high economic impact of RA [2] .
Profound changes in RA treatment paradigms have taken place [1] . Earlier and more aggressive DMARD therapies are instituted to prevent permanent disabilities and disease progression. In line with this development, the introduction of TNF blockers and other biological drugs since 2000 has added a very effective, however costly, escalation option in the control of RA disease activity. The markedly higher medication costs of anti-TNF agents compared with established DMARD combinations sparked the need for economic data on the current development of RA costing. Further relevant economic aspects are costly co-medications and joint replacement surgery.
In a nationwide sample of households, Yelin et al. [3] recently reported details on an increase in overall medical care expenditure attributable to arthritis and other rheumatic conditions in the USA. However, data on cost development specified for different cost domains are still sparse. This topic is of interest as it might be the case that higher costs in the drug sector are offset at least partially by savings in other sectors of health care. Hence, the present investigation aims at a comparison of overall disease-related costs and of cost composition before and after the introduction of TNF blockers in Germany, in order to evaluate the potential economic influence on cost development.
Patients and methods

Patients and study design
Two cohorts of RA outpatients (ACR '87 criteria) with longstanding disease were assessed in terms of disease-related costs and cost composition. The first sample was recruited in 199798 as part of a multi-centre clinical trial on RA, and its predictors also, comprising a piggy-back economic evaluation [4, 5] . The data from the second sample were collected in 2002 during a full-cost analysis linked to a clinical trial assessing quality management in RA [6, 7] . Mean disease duration was 8 years at assessment in both samples. Only patients of working age, who were gainfully employed at the outset of the respective studies, are included in this analysis. Accordingly, a sample of n = 106 patients (55 years, 61% female) with costing data captured in 199798 are compared with a second sample of n = 180 patients (53 years, 69% female) with costing data assessed in 2002 (Table 1) .
Economic evaluation
Full-cost analyses are carried out from the societal perspective including direct disease-related costs (medical and non-medical) and productivity costs. The clinical and economic data are captured by patient questionnaires. For the economic data, the health economic questionnaire for RA patients (HEQ-RA) is employed covering all cost domains according to the current recommendations (OMERACT) [8, 9] .
Costs in absolute terms of all components assessed as well as relative proportions of cost components within the samples are compared employing a discount rate of 5% following current German health economic guidelines [10] . A special focus is given on differences of medication costs and the composition of RA-related medications comparing the pre-and post-era after introduction of TNF-blocking agents.
Direct cost components
The major direct cost components that were found to be reported adequately by patient questionnaires in a previous validation study are considered [11] : costs due to RA-related (i) medication; (ii) inpatient treatment; (iii) outpatient physician visits (including diagnostic and therapeutic outpatient measures); and (iv) non-physician service utilization. Minor cost components are displayed summarized as other direct costs. For the monetary valuation, the following data sources are employed: average market prices for all drugs, German physician fee schedules [the Einheitlicher Bewertungsmabstab (EBM) as a uniform value scale comprising all for remuneration-approved medical services] and official price tariffs for the Statutory Health Insurance [12] .
Productivity cost components
Indirect costs are estimated according to the human capital approach taking a friction period into account. Accordingly, productivity losses are counted only within a limited period of time owing to the fact that the patient's productivity will be replaced assuming that no economy achieves full employment [13, 14] . Productivity losses due to RA-related sick leave, work disability and other loss of work are included. The monetary valuation of productivity losses is based on the German guidelines for health economic evaluation [10] employing population data [15] .
Ethical approval and data protection Prior to enrolment, the patients were informed about the aims and the content of the investigations by specific patient information. Informed consent was given by all patients for their participation and the anonymized data storage and processing by computer data bases. Both studies were approved by the local ethics committee (ethics committee of Hannover Medical School). 
Results
Comparison of patient characteristics
Patient characteristics proved to be comparable in terms of socio-demographic and clinical variables in the two samples (Table 1) . While bodily pain and loss of function are scored a little higher in the sample collected in 2002, disease activity is rated lower (differences not statistically significant).
Disease-related costs
Overall costs are lower in the sample from 2002 (199798: E4280; 2002: E3830; Table 2 ). This overall difference of 11% is not statistically significant. Direct costs outweigh productivity costs in both samples. In 199798, productivity costs accounted for only 35% of overall costs (E1480) and in 2002 for even less (23%; E850). The overall productivity costs are significantly lower (reduction by 43%) in the sample from 2002 and also across all productivity sub-domains (sick leave: 24%; work disability: 92%; other work loss: 81%). Direct costs sum up to E2800 (199798) and E2980 (2002), respectively ( Table 2) . Regarding the main direct cost components, significant differences are seen in the domains medication and hospitalization costs. Medication costs are E550 (199798) and E1580 (2002), respectively, showing almost three-fold higher costs in the sample from 2002. In contrast, the hospitalization costs are significantly lower in 2002 (199798: E1240 vs 2002: E500), almost compensating for the higher medication costs.
Outpatient physician visits, including diagnostic and therapeutic measures and outpatient non-physician service utilization, render comparable costs in both samples (physician visits: E530 vs E540 and non-physician services: E200 vs E180).
Changes in relative weight of different cost domains
The
Medication cost components
Detailed analysis of RA-related medication reveals that not only the costs for DMARDs are higher in 2002, but also all other classes such as steroids, NSAIDs, analgetics, osteoporosis prophylaxis and treatment, and gastroprotective medication. The proportion of these other substance classes increases by 8% (Table 3) .
DMARD costs in 199798 are mostly driven by CSA (6% on CSA treatment) accounting for almost half of overall medication costs. Other relevant contributors are MTX with 18% (employed in 44%), SSZ with 8% (given to 9% of the cohort) and i.m. gold preparations with 8% (given to 11%). In 2002, the main cost drivers are the TNF blockers infliximab (given to 2%) and etanercept (given to 1%) incurring 37% of overall medication costs. Furthermore, CSA (given to 4%), LEF (given to 13%) and MTX (given to Regarding other RA-related medications, six-fold higher costs for steroids can be observed in 2002 (Table 3 ). The frequency of steroid treatment and the mean dosage in regular steroid intake have risen (199798: 35% steroid treatment, 20% regularly, mean dosage 2.8 mg/day; 2002: 74% steroid treatment, 65% regularly, mean dosage 4.1 mg/day). Accordingly, costs for NSAIDs are two-fold higher in 2002, 21% of the patients were given NSAIDs on a regular basis and 20% took NSAIDs as needed in 199798, compared with 32 and 37%, respectively, in 2002. Furthermore, the costs for analgesics, osteoporosis medication and gastroprotective treatment are substantially higher in 2002 as well.
Discussion
Comparison of overall costs
Comparing both patient samples investigated in 199798 and in 2002, a small but not significant decrease is detected in overall costs related to RA per case. Employing comparable standardized measures for the definition of cost components and their valuation, the extent of overall costs is comparable with that of other economic evaluations [1] . Regarding overall costs as well as only direct costs a range of different cost estimates has been described [2] . The most outstanding drivers of the higher estimates are indirect costs, hospitalization costs and medication costs with their extent being dependent on valuation methods chosen, data sources, settings and the respective health-care system [2] . In the present analysis, the cost estimates are to be interpreted in the light of the German health-care system prior to the introduction of the diagnosis-related group (DRG) system for the reimbursement of hospitalization costs. Thus, overall costs range in the lower quartile compared with all other costing studies carried out up to then [2] . For the purpose of the present analysis, it is important that similar methods, data sources and settings have been employed.
There are no cost-of-illness studies available from other countries that render comparable data on RA cost development after the TNF agents were introduced into the treatment. Current research focuses primarily on patient groups in need of biological therapy comparing costs before and under treatment with biologicals in order to explore the cost-effectiveness of these agents. The present analysis aims to show the global impact of these drugs on overall costs in RA as a disease entity. Cost-effectiveness analyses, as recently performed by Sany et al. [17] with original data reveal that the economic changes incurred by biological treatment in a cohort of biological users have to be evaluated regarding long time frames. In the short run, the high medication costs counterbalance most of the economic benefits.
Comparison of cost composition
Overall cost estimates remain virtually unchanged and there is a shift in cost composition. The most outstanding change is a more than two-fold increase in medication (prescription) costs, while costs related to inpatient treatment and indirect costs decrease substantially. 
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German COI study in RA: cost drivers and savings A randomized controlled trial has shown that adalimumab combined with MTX in comparison with MTX alone is more effective in preventing work loss [18] . Hence, this finding might underline the importance of indirect cost components as contributors to cost savings due to innovative treatment. The increase in medication costs within the present observation period has been reported for other rheumatic disease entities as well [3] .
The role of biological drugs in medication cost increase
Since the most outstanding result is the increase in medication costs, their composition has been investigated in detail. A major concern of health-care payers is the high costs related to biological response modifiers that have become available since the year 2000. Our data show that these biological drugs are responsible for a large part of cost increases in this cost domain. However, these agents might also have the potential to positively influence cost savings in other areas of the health-care system aside from the clinical benefits they provide. According to our findings, the incidence of biological treatment was 3% in 2002 following the German guidelines at that time (requiring at least two prior DMARD treatment failures including MTX in active RA at that time, which is still the case today) [19] , presenting a moderate rate of diffusion into daily practice compared with current data in Germany. Interestingly, other relevant components of cost increase covering the remaining half of the overall medication cost could be observed. The most important factors are: (i) the introduction of LEF, which is more costly than MTX or other established medications; (ii) the more frequent use of traditional DMARDs as mono-and combination medication; and (iii) the tendency to use more expensive co-medication in terms of NSAID treatment and osteoporosis prophylaxis. The increase in DMARD use might be reflecting efforts to adhere more strictly to current recommendations of early and aggressive treatment [20] .
Comparing the prescription frequencies of TNF blockers (3% in 2002 as seen in the present investigation) this number was relatively stable over time in Germany till 2006. However, the actual medical need for the initiation of a biological therapy might be three to five times as high as the numbers in the presented cohort. Undoubtedly this will lead to an increasing relative contribution of these new compounds to the overall direct costs. Newer data suggest that the rate of biological treatment among patients with RA who are under continuous care by a rheumatologist is closer to 10% in Germany [21, 22] . However, as not all patients with RA have access to a rheumatologist, this also might give a biased picture for the overall group of RA patients in Germany. As the trend seen in this analysis might be biased by the slow diffusion of the biologicals in Germany, this comparison cannot be repeated with more recent cohorts. This is due to the fact that the composition of the overall patient population in RA in terms of clinical characteristics has dramatically changed as especially the high efficacy of biologicals has had its impact on the positive side from the perspective of affected patients.
Limitations
Although patient characteristics and disease duration of the two samples match well, there might be confounders influencing costing variables that cannot be ruled out. In the present analysis, we have been able to further minimize the risk of confounding by employing identical methods and instruments for the economic assessment and evaluation.
The comparison of our economic data with other studies is impaired by the fact that our data reflect the situation in secondary care and also as delivered by specialized rheumatologists. Cost composition and overall costs might differ in some aspects from primary care where services are provided by general practitioners. Secondary care in RA may be more expensive at first sight compared with primary care; however, there are data available neither on extent or composition, nor on the development of this difference over time.
Conclusions
The present investigation reports on the potential economic impact of introducing costly TNF agents for RA treatment in Germany. More than half of the notable increase in medication cost is attributed to biological compounds. However, despite these rising medication costs, overall RA-related costs remain virtually unchanged comparing the 199798 and 2002 costing data. The incline in medication costs is counterbalanced by decreased hospitalization and productivity costs. Since in a setting of a comparison of two different cohorts confounding cannot be ruled out conclusions have to be drawn carefully. If these economic effects prove to be mainly related to the introduction of the highly effective TNF-blockers, the influence of the achieved cost savings can be expected to further increase over time. Therefore, it appears to be economically highly relevant to validate this assumption in further economic analyses over longer time frames.
Rheumatology key messages
. Substantial parts of the notably increased medication costs are attributable to biological compounds in RA. . The medication cost incline is counterbalanced by savings related to hospitalization and productivity losses. . The present data encourage the further recommendation-based employment of innovative drugs in RA.
